Unknown

Dataset Information

0

Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer.


ABSTRACT: The interaction of programmed death receptor 1 (PD-1) and its ligand, programmed death receptor ligand 1 (PD-L1), negatively regulates immune responses. This study aimed to clarify PD-L1 expression levels in breast cancer through immunohistochemistry (IHC) and to evaluate associations between these findings and clinicopathologic variables, including prognosis.PD-L1 expression was analyzed using IHC on tissue microarrays of 465 invasive breast carcinomas.High PD-L1 expression was demonstrated in 63 of 465 tumors (13.5%). High PD-L1 expression was significantly associated with high histologic grade (p<0.001), negative lymph nodes (p=0.011), early pathologic stage (p=0.025), high tumor-infiltrating lymphocyte (TIL) (p<0.001) counts, negative estrogen receptor (p<0.001) and progesterone receptor (p=0.002) expression, positive human epidermal growth factor receptor 2 (HER2) (p=0.003), cytokeratin 5/6 (p=0.011), epidermal growth factor receptor (p<0.001), and p53 (p<0.001) expression, and high Ki-67 proliferating index (p<0.001). Based on intrinsic subtypes, high PD-L1 expression and high TIL counts were significantly associated with the HER2 and triple-negative basal type (p<0.001). PD-L1 expression was significantly associated with better disease-free survival (DFS) (p=0.041) and overall survival (OS) (p=0.026) in the univariate analysis, but not in the multivariate analysis. Higher TIL levels was an independent prognostic factor for decreased disease progression (hazard ratio [HR], 2.389; 95% confidence interval [CI], 1.284-4.445; p=0.006) and overall death (HR, 3.666; 95% CI, 1.561-8.607; p=0.003).PD-L1 protein expression in breast cancer is associated with better DFS and OS, but is not an independent prognostic factor. High PD-L1 expression was significantly associated with high TIL levels. This finding has important implications for antibody therapies targeting the PD-1/PD-L1 signaling mechanism in breast cancer.

SUBMITTER: Bae SB 

PROVIDER: S-EPMC5053308 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer.

Bae Sang Byung SB   Cho Hyun Deuk HD   Oh Mee-Hye MH   Lee Ji-Hye JH   Jang Si-Hyong SH   Hong Soon Auck SA   Cho Junhun J   Kim Sung Yong SY   Han Sun Wook SW   Lee Jong Eun JE   Kim Han Jo HJ   Lee Hyun Ju HJ  

Journal of breast cancer 20160923 3


<h4>Purpose</h4>The interaction of programmed death receptor 1 (PD-1) and its ligand, programmed death receptor ligand 1 (PD-L1), negatively regulates immune responses. This study aimed to clarify PD-L1 expression levels in breast cancer through immunohistochemistry (IHC) and to evaluate associations between these findings and clinicopathologic variables, including prognosis.<h4>Methods</h4>PD-L1 expression was analyzed using IHC on tissue microarrays of 465 invasive breast carcinomas.<h4>Result  ...[more]

Similar Datasets

| S-EPMC4490866 | biostudies-other
| S-EPMC5400624 | biostudies-literature
| S-EPMC8403354 | biostudies-literature
| S-EPMC1805580 | biostudies-literature
| S-EPMC8601953 | biostudies-literature
| S-EPMC10205737 | biostudies-literature
| S-EPMC6361576 | biostudies-literature
| S-EPMC7693484 | biostudies-literature
| S-EPMC5343992 | biostudies-literature
| S-EPMC8505298 | biostudies-literature